ClinicalTrials.gg
CompletedNCT03482765Updated Jul 5, 2019

A Study of Probiotics in IBS Subjects

An interventional study of Probiotic 1 and Probiotic 2 in IBS, sponsored by Vedic Lifesciences Pvt. Ltd.. Completed at 12 sites in India. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-05.

Sponsored by Vedic Lifesciences Pvt. Ltd. · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

For the current study, the primary outcome is to evaluate the effect of IP on abdominal pain.

The secondary outcome is to assess the effect of IP on IBS-Symptom Severity, IBS-related quality of life, stool form and consistency and on mental status.

Thus providing an effective objective in improving the gut health and symptomatic relief in IBS patients.

Read the detailed description

This study aims to determine the effect of probiotics, as the investigational products (IPs) in subjects satisfying the Rome IV criteria for IBS. Three hundred and sixty six subjects between 18 to 70 years of age and with a positive diagnosis of Rome IV IBS criteria (IBS-C, D, M and U types) and moderate to severe abdominal pain intensity will be recruited in a multi-center, double-blind, parallel group, placebo-controlled randomized trial.

02

Conditions studied

  • IBS
03

In context

Lead sponsor

Vedic Lifesciences Pvt. Ltd. is the lead sponsor of 72 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Literate (as defined by the basic capability to read and understand in the languages approved for the study), male and female subjects in age range of 18-70 years.
  • Presence of Rome IV diagnostic criteria for IBS.

Exclusion criteria

Exclusion Criteria:

  • Anemic subjects with \< 10 g/dl.
  • Subjects with organic disease (to be ruled out by physician based on prior history and physical examination).
  • Subjects with a history of surgical resection of the stomach, small intestine or large intestine.
  • Subjects with a history of or complications from inflammatory bowel disease (Crohn's disease or ulcerative colitis) and ischemic colitis.
  • Subjects with complications from infectious enteritis, hyperthyroidism or hypothyroidism.
  • Subjects with a history of any diet-based intolerance (gluten or lactose intolerance).
  • Subjects with a history of drug or alcohol abuse within the past 6 months.
  • Subjects with a history of or complications from malignant tumors.
  • Subjects with severe depression or an anxiety disorder, which could potentially affect the efficacy evaluation (as determined by the qualified investigator).
  • Subjects with uncontrolled hypertension (≥140/90 mm Hg).
  • Subjects with complications from serious cardiovascular diseases, respiratory diseases, endocrinological and gynecological disorder, renal diseases, hepatic diseases, gastrointestinal diseases (excluding IBS), blood diseases or neurological or psychiatric diseases.
  • Subjects who are pregnant, breastfeeding or planning on becoming pregnant throughout the course of the study.
  • Subjects with a history of dysmenorrhea.
  • Subjects with any unstable medical conditions.
  • Subjects with uncontrolled Type II diabetes mellitus.
  • Subjects with a history of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years after diagnosis are acceptable.
  • Subjects who are immuno-compromised ( positive, on anti-rejection medication, rheumatoid arthritis).
  • Subjects with any medical condition or a history of abdominal surgery that is deemed exclusionary by the qualified investigator.
  • Subjects with an active eating disorder.
  • Subjects who have used an over-the-counter or prescription laxative medication or any other herbal agents affecting GI motility within 2 weeks prior to screening.
  • Subjects who have used probiotic or fiber supplements (or probiotic/fiber enriched foods) or an antibiotic within 4 weeks prior to screening.
  • Subjects who have used IBS specific treatments within 4 weeks prior to screening.
  • Subjects who currently consume greater than 2 standard alcoholic drinks per day from past 3 months.
  • Subjects who smoke ≥ 1 cigarette per day. Occasional (Non-daily) smokers will be allowed.
  • Subjects who have participated in a clinical research trial within 30 days prior to randomization.
  • Subjects with an allergy or sensitivity to the probiotic products.
  • Subjects who are cognitively impaired and/or who are unable to give an .
  • Subjects who have abnormal laboratory results or any other medical or psychological condition which, in the opinion of the qualified investigator, may adversely affect the subjects' ability to complete the study or its measures or which may pose significant risk to the subject.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
336 participants (actual)

Study arms

  • Experimental
    Probiotic 1

    Probiotic 1: A dietary probiotic supplement which contains Bifidobacterium lactis. Dose: \> 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.

    Dietary Supplement: Probiotic 1

  • Experimental
    Probiotic 2

    Probiotic 2: A dietary probiotic supplement which contains Lactobacillus acidophilus. Dose: \> 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.

    Dietary Supplement: Probiotic 2

  • Placebo comparator
    Placebo

    The Placebo contains MCC.

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in abdominal pain severity

    The change at Day 42 will be assessed by subject dairy.

    Time frame: 42 days

Secondary outcomes

  1. Change in abdominal pain severity

    The change at Day 21 will be assessed by subject dairy

    Time frame: Day 21

  2. Change in IBS symptoms

    The change at Day 42 will be compared to baseline

    Time frame: Day 42

  3. Change in stool consistency

    The change at Day 42 will be compared to baseline by specific questionnaire

    Time frame: Day 42

  4. Change in Quality of Life

    The change at Day 42 will be compared to baseline by specific questionnaire

    Time frame: Day 42

  5. Change in daily number of stools

    The change at Day 42 will be compared to baseline

    Time frame: Day 42

07

Study locations

12 sites
  • Apex Gastro Clinic
    Ahmedabad, Gujrat 380013, India
  • Gastrocare & Liver Clinic
    Ahmedabad, Gujrat 380015, India
  • The Gut Clinic
    Mumbai, Maharashtra 400012, India
  • Vazifdar Clinic
    Mumbai, Maharashtra 400055, India
  • Stress Test Clinic
    Mumbai, Maharashtra 400059, India
  • Shantaee Nursing Home
    Mumbai, Maharashtra 400067, India
  • Dr Sanjeev Khanna's Clinic
    Mumbai, Maharashtra 400069, India
  • Ameeta Nursing home
    Mumbai, Maharashtra 400071, India
  • Lancelot Kidney and GI Center
    Mumbai, Maharashtra 400092, India
  • Kshirsagar Nursing Home
    Mumbai, Maharashtra 400602, India
  • Samarth Clinic
    Navi Mumbai, Maharashtra 400703, India
  • Sampada Hospital
    Thāne, Maharashtra 400601, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Mar 2019, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2018
First posted
Mar 29, 2018
StartActual
Mar 30, 2018
Primary completionActual
Mar 14, 2019
CompletionActual
Jun 30, 2019
Last update
Jul 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03482765
Responsible party
Sponsor
First posted
Mar 29, 2018
Start date
Mar 30, 2018
Primary completion
Mar 14, 2019
Completion
Jun 30, 2019
Last update
Jul 5, 2019

Study contacts

Shalini Srivastava, M.D.
study director · Vedic Lifesciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bifidobacterium animalis subsp. lactis · Lacteol

Start the discussion